Researchers at St. Luke’s Mid America Heart Institute report that patients who received an innovative valve therapy demonstrated markedly improved quality of life, according to a study released Nov. 10 at the 23rd Annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco.

Researchers at St. Luke’s Mid America Heart Institute report that patients who received an innovative valve therapy demonstrated markedly improved quality of life, according to a study released Nov. 10 at the 23rd Annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco.

The Partner trial was the world’s first randomized, controlled pivotal trial of a transcatheter aortic heart valve, a collapsible valve that can be introduced into the body through a catheter-based delivery system via one of two approaches: Through a small incision through the groin (similar to coronary angioplasty or stenting) or between the ribs. The valve replaces a patient’s diseased “native” valve without traditional open-heart surgery and while the patient’s heart continues to beat.

The device was approved on Nov. 2 by the Food and Drug Administration for transfemoral delivery of the valve for the treatment of inoperable patients with severe aortic stenosis.

For more information, visit www.crf.org.